PET tracer agent of targeted FAP receptor and preparation method of PET tracer agent

By developing a PET tracer (S)-N-(2-(2-cyanopyrrolidine-1-yl)-2-oxyethyl)-7-(4-fluorophenyl)) targeting FAP receptors Quinoline-4-formamide and its preparation method solve the problem that it is difficult to effectively target and diagnose FAP receptors in tumors in the prior art, realize efficient imaging of FAP receptors, and provide tumor diagnosis and treatment. New ideas.

CN118978509APending Publication Date: 2024-11-19ZHEJIANG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411069819.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively target and diagnose FAP receptors in tumors, which affects the early detection and treatment effects of tumors.

Method used

A PET tracer targeting FAP receptors (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxyethyl)-7-(4-fluorobenzene The tracer is synthesized by a series of compound reaction steps and is used in PET imaging technology.

Benefits of technology

A new type of targeted FAP receptor PET tracer 19F-FAP-QGF is provided, which realizes efficient imaging of FAP receptors and provides new ideas and methods for tumor diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978509A_ABST
    Figure CN118978509A_ABST
Patent Text Reader

Abstract

The invention provides a PET (Polyethylene Terephthalate) tracer agent of a targeted FAP (Fibroblast Amplification Protein) receptor and a preparation method of the PET tracer agent. The structure of a novel PET tracer agent 19F-FAP-QGF of the targeted FAP receptor is provided for the first time; the invention also provides a route of the PET tracer agent 19F-FAP-QGF of the targeted FAP receptor, corresponding reaction steps and structural characterization of the PET tracer agent 19F-FAP-QGF of the targeted FAP receptor. The invention provides a synthetic route of the precursor FAP-QGN, corresponding reaction steps and structural characterization, and provides a thought for synthesizing the 18F-FAP-QGF probe for FAP target tumor diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of radiopharmaceuticals and nuclear medicine, and in particular to a PET tracer targeting FAP receptors and a preparation method thereof. Background Art

[0002] The TME is composed of immune cells, blood vessels, extracellular matrix, and cancer-associated fibroblasts (CAFs). Treatment failure may result from the development of an immunosuppressive TME that shields tumor cells from the effects of therapeutic agents. In solid tumors, CAFs are one of the most prevalent components of the TME. However, CAFs are heterogeneous cells, and various conditions have been shown to induce both tumor-promoting and tumor-suppressive activities. They are able to remodel the ECM structure, thereby promoting tumorigenesis, neovascularization, and metastasis. This can act both as a physical barrier to prevent the infiltration of immune cells and as a structural scaffold to promote cell-to-cell interactions between tumor cells and non-tumor cells in the TME. On the downside, CAFs can release a variety of chemokines and cytokines, including interleukin-6 (IL-6), CC-chemokine ligand 2, and transforming growth factor (TGF), to attract suppressive immune cell subsets in the tumor stroma, thereby promoting immune evasion. Platelet-derived growth factor receptor-β (PDGFR-β), α-smooth muscle actin (α-SMA), and fibroblast activation protein (FAP) are just a few of the biomarkers found in CAFs. FAP is a type II integral membrane glycoprotein from the serine protease family with roles in fibrogenesis and ECM remodeling. Due to the widespread distribution of FAP in many cancer types (e.g., sarcomas, prostate cancer, breast cancer, lung cancer, pancreatic cancer, head and neck cancer, colorectal cancer), the question arises whether FAP could be a new therapeutic target for cancer (e.g., Figure 1 (shown)

[0003] Carcinoma associated fibroblasts (CAFs) are important components of the tumor microenvironment. Fibroblast activation protein-α (FAP-α) is a serine protease and a transmembrane protein with 760 amino acids. Its gene is located at 2q23. It is mostly expressed during development and rarely expressed in healthy adult tissues. However, FAP is highly upregulated in pathological tissue remodeling sites (including cancer, fibrosis, arthritis, wounds or inflammation), especially on fibroblasts. Studies have shown that FAP-α plays an important role in tumor generation, invasion and metastasis. Detection of FAP-α expression in tumors can become an indicator of tumor prognosis. FAP-α also provides a new means for future tumor treatment because it is a regulator of tumor chemotherapy sensitivity. The tumor stroma has been increasingly recognized as an important player in tumorigenesis, drug resistance, angiogenesis, invasion and metastasis. The stroma is composed of cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM). FAP, as a marker of CAFs, is involved in regulating the extracellular matrix and has many functions that promote tumor activity.

[0004] Positron Emission Tomography (PET) is currently the only new imaging technology that can display biological molecular metabolism, receptor and neurotransmitter activities in vivo. It is now widely used in the diagnosis and differential diagnosis of various diseases, efficacy evaluation, organ function research and new drug development. PET imaging technology has high sensitivity, high specificity and strong penetration, and it can image the whole body. A one-time whole-body imaging examination can obtain images of all areas of the body. PET is an imaging that reflects molecular metabolism. When the disease is in the early stage of molecular level changes, the morphological structure of the lesion area has not yet shown abnormalities, and MRI and CT examinations cannot make a clear diagnosis, PET examinations can find the location of the lesion, obtain three-dimensional images, and perform quantitative analysis to achieve early diagnosis, which is unmatched by other imaging examinations.

[0005] PET tracers, also known as PET imaging agents, are radioactive drugs that are labeled with positron-emitting radionuclides and introduced into the body to perform organ, tissue or molecular imaging. After the radioactive drug is introduced into the body, it can gather in the target organ or tissue, and the rays emitted by it are detected by imaging instruments to obtain images of the drug's distribution in the body, which is used to diagnose a variety of diseases. Glucose, such as 18-fluoro-deoxyglucose (18F-FDG), is the most common positron imaging agent in PET probes, and has been studied in depth in tumor diagnosis and treatment. Summary of the invention

[0006] The present invention aims to address the deficiencies of the prior art and to provide a PET tracer targeting FAP receptors and a preparation method thereof.

[0007] The object of the present invention is achieved through the following technical solution: a PET tracer targeting FAP receptor, the tracer is (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide, and its chemical structure is as follows:

[0008]

[0009] On the other hand, the present invention also provides a method for preparing a PET tracer targeting a FAP receptor, the specific steps of which are as follows:

[0010] (1) dissolving 6-bromo-1H-indole-2,3-dione in a sodium hydroxide aqueous solution, heating and refluxing, adding sodium pyruvate to react, adjusting the pH, adding water, filtering and drying to obtain 7-bromoquinoline-2,4-dicarboxylic acid, then adding water and heating and refluxing, filtering and drying to obtain 7-bromoquinoline-4-carboxylic acid for later use;

[0011] (2) dissolving Boc-glycine in N,N-dimethylformamide, adding HOBT, EDCI and triethylamine under ice bath conditions, and adding L-co-aminoamide after a period of reaction; continuing the reaction for a period of time, diluting with saturated brine and extracting with ethyl acetate, combining the organic phases, washing, drying with anhydrous sodium sulfate, filtering and concentrating to obtain a crude product, beating with dichloromethane / n-hexane = 1 / 5, filtering to obtain (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamic acid tert-butyl ester;

[0012] (3) Tert-butyl (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamate is dissolved in tetrahydrofuran, and pyridine, trifluoroacetic anhydride and dichloromethane are added dropwise under nitrogen atmosphere and ice bath conditions. After reaction for a period of time, the mixture is concentrated by rotary evaporation to remove the solvent and then redissolved in ethyl acetate. After washing, the mixture is dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product is then repeatedly rotary evaporated with dichloromethane and methanol for several times to obtain tert-butyl (S)-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamate. The crude product is dissolved in methanol, concentrated hydrochloric acid is added and reacted for a period of time. The mixture is concentrated by rotary evaporation to remove the solvent and then repeatedly evaporated with dichloromethane and methanol for several times to obtain (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride for use;

[0013] (4) dissolving the 7-bromoquinoline-4-carboxylic acid obtained in step (1) in N,N-dimethylformamide, adding HOBT, EDCI and N,N-diisopropylethylamine under ice bath conditions, adding (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride obtained in step (3) after a period of reaction, and continuing the reaction for a period of time, diluting with saturated brine and extracting with ethyl acetate, combining the organic phases, washing, drying with anhydrous sodium sulfate, filtering and concentrating to obtain a crude product, and purifying to obtain (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide;

[0014] (5) (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide and 4-fluorophenylboric acid are dissolved in tetrahydrofuran and water, methyl carbonate and tetrakis(triphenylphosphine)palladium are added, and the mixture is reacted for a period of time under nitrogen atmosphere protection, and then diluted with water and extracted with ethyl acetate; the organic phases are combined, washed, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which is purified to obtain (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide.

[0015] Further, N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is dissolved in dichloromethane, methyl trifluoromethanesulfonate is added dropwise under ice bath conditions, and after a period of reaction, the mixture is filtered, washed with dichloromethane, and dried to obtain N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline for use;

[0016] The (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide and N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline prepared in step (4) are dissolved in N,N-dimethylformamide and water, and cesium carbonate and tetrakis(triphenylphosphine)palladium are added. The mixture is reacted for a period of time under the protection of a nitrogen atmosphere. After the reaction is completed, the mixture is diluted with water and extracted with ethyl acetate. The organic phases are combined, washed, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which is purified to obtain (S)-4-(4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinoline-7-yl)-N,N,N-trimethylaniline.

[0017] Furthermore, in step (1), the reaction conditions after adding sodium pyruvate are: heating to 110° C., reacting for four hours, cooling the room temperature to 25° C., and then adjusting the pH.

[0018] Furthermore, in step (2), after reacting at room temperature for 15 minutes, L-co-amino amide was added, and the reaction was continued at room temperature for 16 hours, and then diluted with saturated brine and extracted with ethyl acetate.

[0019] Furthermore, in step (4), after reacting at room temperature for 15 minutes, (S)-1-glycylglycine-2-carbonitrile hydrochloride was added, and the reaction was continued at room temperature for 16 hours, and then saturated brine was added for dilution, and extraction was performed with ethyl acetate.

[0020] Furthermore, in step (5), the chromatography column used for purification is dichloromethane / methanol = 100 / 0 / 0-20 / 1.

[0021] Further, the chromatography column used for purification to obtain (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide was dichloromethane / methanol / triethylamine = 100 / 0 / 0-10 / 1 / 0.01

[0022] Beneficial effects of the present invention: The present invention proposes for the first time a structure of a novel PET tracer 19F-FAP-QGF targeting FAP receptors; the present invention provides a route of the PET tracer 19F-FAP-QGF targeting FAP receptors and corresponding reaction steps and structural characterization; the present invention provides a synthesis route of a precursor FAP-QGN and corresponding reaction steps and structural characterization, providing a method for synthesizing a 18F-FAP-QGF probe for FAP target tumor diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0024] Figure 1 Schematic diagram of FAP as a therapeutic target for cancer.

[0025] Figure 2 This is the nuclear magnetic resonance mass spectrum characterization spectrum of compound 10 in the method for preparing FAP-QGF provided by the present invention. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described below in conjunction with the accompanying drawings and implementation examples. It should be understood that the specific implementation examples described herein are only used to explain the present invention and are not used to limit the present invention.

[0027] like Figure 2 As shown, the present invention provides a method for preparing the following compounds:

[0028]

[0029] (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide

[0030] The steps include:

[0031] 1) 6-Bromo-1H-indole-2,3-dione (molecule 1) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. with production batch number B124372-25g.

[0032] 2) 6-bromo-1H-indole-2,3-dione (molecule 1) (8.72 g, 38.6 mmol, 1 eq) was dissolved in a 3 M sodium hydroxide aqueous solution, heated to reflux, and sodium pyruvate (5.09 g, 46.3 mmol, 1.2 eq) was added and the temperature was raised to 110°C. The reaction was allowed to proceed for four hours, and the room temperature was cooled to 25°C. The pH was adjusted to 3-4 using 1 M HCl, and the mixture was filtered, washed with water, and dried to obtain 7-bromoquinoline-2,4-dicarboxylic acid (molecule 2);

[0033]

[0034] 3) 7-bromoquinoline-2,4-dicarboxylic acid (molecule 2) (1 g, 3.38 mmol, 1 eq) was added with water (60 mL, 60 V), heated to 200 ° C in a muffle furnace, refluxed for 10 hours, filtered, washed and dried to obtain 7-bromoquinoline-4-carboxylic acid (molecule 3);

[0035]

[0036] 4) Boc-glycine (molecule 4) (5g, 28.5mmol, 1eq) was dissolved in N,N-dimethylformamide (75mL, 15V), and HOBT (11.57g, 85.5mmol, 3eq), EDCI (10.94g, 87.3mmol, 2eq) and triethylamine (11.9mL, 85.5mmol, 3eq) were added under ice bath conditions; after reacting at room temperature for 15 minutes, L-co-aminoamide (3.26g, 28.5mmol, 1eq) was added. The reaction was continued at room temperature for 16 hours. Saturated brine was added for dilution and extracted with ethyl acetate; the organic phases were combined, washed with saturated brine for 3 times, dried with anhydrous sodium sulfate, filtered, washed and concentrated to obtain a crude product. The crude product was slurried with dichloromethane / n-hexane = 1 / 5 and filtered to obtain (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamic acid tert-butyl ester (molecule 5);

[0037]

[0038] 5) Tert-butyl (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamate (molecule 5) (8.4 g, 30.9 mmol, 1 eq) was dissolved in tetrahydrofuran (672 mL, 80 V), and pyridine (17.5 mL, 216.3 mmol, 7 eq), trifluoroacetic anhydride (5.05 mL, 35.5 mmol, 1.15 eq) and dichloromethane (10 mL, 1.2 V) were added dropwise under nitrogen atmosphere and ice bath conditions. The mixture was reacted at room temperature for 90 minutes. The solvent was removed by rotary evaporation and the crude product was redissolved in ethyl acetate, washed with saturated brine three times, and then dried with anhydrous sodium sulfate, filtered, washed and concentrated to obtain the crude product. The crude product was repeatedly rotary evaporated with dichloromethane and methanol three times to obtain tert-butyl (S)-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamate (molecule 6);

[0039]

[0040] 6) Tert-butyl (S)-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamate (molecule 6) (1g, 3.95mmol, 1eq) was dissolved in methanol (8mL, 8V) and concentrated hydrochloric acid (4mL, 4V) was added. The mixture was reacted at room temperature for 1 hour. The solvent was removed by rotary evaporation and the crude product was repeatedly treated with dichloromethane and methanol for 3 times to obtain (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride (molecule 7);

[0041]

[0042] 7) 7-Bromoquinoline-4-carboxylic acid (molecule 3) (387 mg, 1.53 mmol, 1 eq) was dissolved in N,N-dimethylformamide (5.8 mL, 15 V), and HOBT (622.3 mg, 4.60 mmol, 3 eq), EDCI (588.6 mg, 3.07 mmol, 2 eq) and N,N-diisopropylethylamine (1.6 mL, 9.18 mmol, 6 eq) were added under ice bath conditions; after reacting at room temperature for 15 minutes, (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride (molecule 7) (291.1 mg, 1.53 mmol, 1 eq) was added. The reaction was continued at room temperature for 16 hours. Saturated brine was added for dilution, and ethyl acetate was used for extraction; the organic phases were combined, washed with saturated brine for 3 times, dried with anhydrous sodium sulfate, filtered, washed, and concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane / methanol = 100 / 0-25 / 1) to obtain (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide (molecule 8);

[0043]

[0044] 8) N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (molecule 9) (3.0 g, 12.1 mmol, 1 eq) was dissolved in dichloromethane (30 mL, 10 V), and methyl trifluoromethanesulfonate (2.98 g, 18.1 mmol, 1.5 eq) was added dropwise under ice bath conditions. The mixture was reacted at 0°C for 3 hours. The mixture was filtered, washed with dichloromethane, and dried to obtain N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (molecule 10);

[0045]

[0046] 9) (S)-7-Bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide (molecule 8) (100 mg, 0.26 mmol, 1 eq) and N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (molecule 10) (160 mg, 0.39 mmol, 1.5 eq) were dissolved in N,N-dimethylformamide (2 mL, 20 V) and water (0.2 mL, 2 V), and cesium carbonate (254.1 mg, 0.78 mmol, 3 eq) and tetrakis(triphenylphosphine)palladium (29.9 mg, 0.026 mmol, 0.1 eq) were added. The mixture was reacted at 100°C for 4 hours under nitrogen atmosphere. After the reaction is completed, dilute with water and extract with ethyl acetate; combine the organic phases, wash with saturated brine three times, dry with anhydrous sodium sulfate, filter, wash, and concentrate to obtain a crude product. The crude product is purified by chromatography column (dichloromethane / methanol / triethylamine = 100 / 0 / 0-10 / 1 / 0.01) to obtain (S)-4-(4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-7-yl)-N,N,N-trimethylaniline (molecule FAP-QGN), which is used to target FAP protein, experimental treatment or diagnosis;

[0047]

[0048] 10) (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide (molecule 8) (100 mg, 0.26 mmol, 1 eq) and 4-fluorophenylboric acid (52 mg, 0.39 mmol, 1.5 eq) were dissolved in tetrahydrofuran (2 mL, 20 V) and water (0.2 mL, 2 V), and methyl carbonate (107.6 mg, 0.78 mmol, 3 eq) and tetrakis(triphenylphosphine)palladium (29.9 mg, 0.026 mmol, 0.1 eq) were added. The mixture was reacted at 80 ° C for 8 hours under nitrogen atmosphere. After the reaction was completed, it was diluted with water and extracted with ethyl acetate; the organic phases were combined, washed with saturated brine 3 times, dried with anhydrous sodium sulfate, filtered, washed, and concentrated to obtain a crude product. The crude product was purified by chromatography (dichloromethane / methanol = 100 / 0-20 / 1, the volume ratio of dichloromethane / methanol was gradually reduced from 100:0 to 20:1) to obtain (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide (molecule FAP-QGF);

[0049]

[0050] The above embodiments are used to illustrate the present invention rather than to limit the present invention. Any modification and change made to the present invention within the spirit of the present invention and the protection scope of the claims shall fall within the protection scope of the present invention.

Claims

1. A PET tracer targeting FAP receptor, characterized in that: The tracer is (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide, and its chemical structure is as follows:

2. A method for preparing a PET tracer targeting FAP receptor, characterized in that: The specific steps are as follows: (1) dissolving 6-bromo-1H-indole-2,3-dione in a sodium hydroxide aqueous solution, heating and refluxing, adding sodium pyruvate to react, adjusting the pH, adding water, filtering and drying to obtain 7-bromoquinoline-2,4-dicarboxylic acid, then adding water and heating and refluxing, filtering and drying to obtain 7-bromoquinoline-4-carboxylic acid for later use; (2) dissolving Boc-glycine in N,N-dimethylformamide, adding HOBT, EDCI and triethylamine under ice bath conditions, and adding L-co-aminoamide after a period of reaction; continuing the reaction for a period of time, diluting with saturated brine and extracting with ethyl acetate, combining the organic phases, washing, drying with anhydrous sodium sulfate, filtering and concentrating to obtain a crude product, beating with dichloromethane / n-hexane = 1 / 5, filtering to obtain (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamic acid tert-butyl ester; (3) Tert-butyl (S)-(2-(2-carbamoylpyrrolidin-1-yl)-2-oxoethyl)carbamate is dissolved in tetrahydrofuran, and pyridine, trifluoroacetic anhydride and dichloromethane are added dropwise under nitrogen atmosphere and ice bath conditions. After reaction for a period of time, the mixture is concentrated by rotary evaporation to remove the solvent and then redissolved in ethyl acetate. After washing, the mixture is dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product is then repeatedly rotary evaporated with dichloromethane and methanol for several times to obtain tert-butyl (S)-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamate. The crude product is dissolved in methanol, concentrated hydrochloric acid is added and reacted for a period of time. The mixture is concentrated by rotary evaporation to remove the solvent and then repeatedly evaporated with dichloromethane and methanol for several times to obtain (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride for use; (4) dissolving the 7-bromoquinoline-4-carboxylic acid obtained in step (1) in N,N-dimethylformamide, adding HOBT, EDCI and N,N-diisopropylethylamine under ice bath conditions, adding (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride obtained in step (3) after a period of reaction, and continuing the reaction for a period of time, diluting with saturated brine and extracting with ethyl acetate, combining the organic phases, washing, drying with anhydrous sodium sulfate, filtering and concentrating to obtain a crude product, and purifying to obtain (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide; (5) (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide and 4-fluorophenylboric acid are dissolved in tetrahydrofuran and water, methyl carbonate and tetrakis(triphenylphosphine)palladium are added, and the mixture is reacted for a period of time under nitrogen atmosphere protection, and then diluted with water and extracted with ethyl acetate; the organic phases are combined, washed, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which is purified to obtain (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-7-(4-fluorophenyl)quinoline-4-carboxamide.

3. The method for preparing a PET tracer targeting FAP receptor according to claim 2, characterized in that: Dissolve N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline in dichloromethane, add methyl trifluoromethanesulfonate dropwise under ice bath condition, react for a period of time, filter, wash with dichloromethane, and dry to obtain N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline for use; The (S)-7-bromo-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide and N,N,N-trimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline prepared in step (4) are dissolved in N,N-dimethylformamide and water, and cesium carbonate and tetrakis(triphenylphosphine)palladium are added. The mixture is reacted for a period of time under the protection of a nitrogen atmosphere. After the reaction is completed, the mixture is diluted with water and extracted with ethyl acetate. The organic phases are combined, washed, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which is purified to obtain (S)-4-(4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinoline-7-yl)-N,N,N-trimethylaniline.

4. The method for preparing a PET tracer targeting FAP receptor according to claim 2, characterized in that: In step (1), the reaction conditions after adding sodium pyruvate are: heating to 110° C., reacting for four hours, cooling the room temperature to 25° C., and then adjusting the pH.

5. The method for preparing a PET tracer targeting FAP receptor according to claim 2, characterized in that: In step (2), after reacting at room temperature for 15 minutes, L-co-amino amide is added, and the reaction is continued at room temperature for 16 hours, and then diluted with saturated brine and extracted with ethyl acetate.

6. The method for preparing a PET tracer targeting FAP receptor according to claim 2, characterized in that: In step (4), after reacting at room temperature for 15 minutes, (S)-1-glycylpyrrolidine-2-carbonitrile hydrochloride is added, and the reaction is continued at room temperature for 16 hours, and then saturated brine is added for dilution, and extraction is performed with ethyl acetate.

7. The method for preparing a PET tracer targeting FAP receptor according to claim 2, characterized in that: In step (5), the chromatography column used for purification is dichloromethane / methanol = 100 / 0-20 / 1.

8. The method for preparing a PET tracer targeting FAP receptor according to claim 3, characterized in that: The chromatography column used for purification was dichloromethane / methanol / triethylamine = 100 / 0 / 0-10 / 1 / 0.01.

Citation Information

Patent Citations

  • Video providing method, server and user terminal device

    KR102236757B1

  • Novel FAP inhibitors

    US20140357650A1